Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults

The immunogenicity of the candidate tuberculosis (TB) vaccine MVA85A may be enhanced by aerosol delivery. Intradermal administration was shown to be safe in adults with latent TB infection (LTBI), but data are lacking for aerosol-delivered candidate TB vaccines in this population. We carried out a P...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Riste, M, Marshall, JL, Satti, I, Harris, SA, Wilkie, M, Lopez Ramon, R, Wright, D, Wittenberg, RE, Vermaak, S, Powell Doherty, R, Lawrie, A, Conlon, CP, Cosgrove, C, Gleeson, F, Lipman, M, Moss, P, Perrin, F, Dedicoat, M, Bettinson, H, McShane, H
Formato:	Journal article
Idioma:	English
Publicado em:	MDPI 2021

Registos relacionados

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <em>M.tb</em>-Infected Adults
Por: Michael Riste, et al.
Publicado em: (2021-04-01)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
Por: Thomas, Z, et al.
Publicado em: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
Por: Tameris, M, et al.
Publicado em: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
Por: Tameris, M, et al.
Publicado em: (2014)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
Por: Mcshane, H
Publicado em: (2008)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
Por: Manjaly Thomas, Z, et al.
Publicado em: (2019)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
Por: Rowland, R, et al.
Publicado em: (2012)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
Por: Michele Tameris, et al.
Publicado em: (2014-01-01)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
Por: Harris, S, et al.
Publicado em: (2011)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
Por: Meyer, J, et al.
Publicado em: (2013)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
Por: Meyer, J, et al.
Publicado em: (2013)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
Por: Zita-Rose Manjaly Thomas, et al.
Publicado em: (2019-04-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
Por: Anne Wajja, et al.
Publicado em: (2017-05-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
Por: Wajja, A, et al.
Publicado em: (2017)

Phase I/II clinical trial of MVA85A in individuals with latent tuberculosis: The first subunit TB vaccine in clinical trial
Por: Sander, C, et al.
Publicado em: (2005)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
Por: Minassian, A, et al.
Publicado em: (2011)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
Por: Harris, S, et al.
Publicado em: (2013)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
Por: Odutola, A, et al.
Publicado em: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
Por: Odutola, A, et al.
Publicado em: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
Por: Dieye, T, et al.
Publicado em: (2013)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults
Por: Wilkie, M, et al.
Publicado em: (2019)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
Por: Whelan, K, et al.
Publicado em: (2009)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
Por: Pathan, A, et al.
Publicado em: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
Por: Pathan, A, et al.
Publicado em: (2012)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
Por: Owiafe, P, et al.
Publicado em: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
Por: Tandakha N Dieye, et al.
Publicado em: (2013-01-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
Por: Kathryn T. Whelan, et al.
Publicado em: (2011-01-01)

TB vaccine development: where are we and why is it so difficult?
Por: Wilkie, M, et al.
Publicado em: (2014)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.
Por: Tandakha N. Dieye, et al.
Publicado em: (2013-01-01)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
Por: Minhinnick, A, et al.
Publicado em: (2016)

Diagnosis of extrapulmonary TB: Experience with the Xpert MTB/Rif assay
Por: C.N. Govind, et al.
Publicado em: (2014-04-01)

Evaluation of Xpert MTB/RIF assay for the diagnosis of paediatric TB
Por: F. Ismail, et al.
Publicado em: (2014-04-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
Publicado em: (2011-01-01)

Diagnostic performance of GeneXpert MTB/RIF in detecting MTB in smear-negative presumptive TB patients
Por: Raksha Rimal, et al.
Publicado em: (2022-04-01)

Impact of introduction of Xpert MTB/RIF test on tuberculosis (TB) diagnosis in a city with high TB incidence in Brazil.
Por: Giovana Rodrigues Pereira, et al.
Publicado em: (2018-01-01)

Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB.
Por: Neeraj Raizada, et al.
Publicado em: (2014-01-01)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
Por: Mcshane, H, et al.
Publicado em: (2016)

TB or not TB?
Por: Andrew Pirotte, et al.
Publicado em: (2024-04-01)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
Por: Satti, I, et al.
Publicado em: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
Por: Satti, I, et al.
Publicado em: (2014)